COVID-19 Update. Learn More

Risankizumab (trade name Skyrizi) effective for plaque psoriasis – MD Magazine

nurse working in medical laboratory. Model signs the model release

Long-term results from the phase 3 IMMhance study of risankizumab (Skyrizi) in patients with psoriasis indicated that a significant number of patients receiving risankizumab maintained complete skin clearance at week 94.

“Results show that Skyrizi has the potential to provide long-term relief from the signs and symptoms of psoriasis,” said Marek Honczarenko, MD, PhD, vice president, immunology development, AbbVie.

In this study, patients who reached a score of clear or almost clear on the static Physician Global Assessment (sPGA 0/1) at week 28 were randomized to either continue on risankizumab or placebo. Of those with continuous treatment with risankizumab, 73% achieved a sPGA of 0 and 72% reached a 100% improvement in the Psoriasis Area and Severity Index (PASI 100).

Read more about the study.

Credt: www.mdmag.com

Thinking of visiting Toronto’s premier skin clinic soon?

Fill out the inquiry form below and let us know your area of interest.

  • Optional

Call us today @ 416.633.0001

    0
    Shopping Bag
    Your cart is emptyReturn to Shop
      Calculate Shipping
      Apply Coupon
      Available Coupons
      comp10 Get 10% off Complimentary 10% for unhappy patients
      gina15 Get 15% off
      laurskin15 Get 15% off Instagram collab with Laurshaps - 15% off
      tdcperks15 Get 15% off
      tdcseniors10 Get 10% off
      tdcstudents10 Get 10% off
      welcome10 Get 10% off
      Unavailable Coupons
      adamweiner Get 10% off Instagram collab with weiner.adam
      uvnvtr2u Get 0% off Test Free Shipping